Cu-related drugs and proteins, such as tetrathiomolybdate (TTM; a potential NF-κB transcription inhibitor), transgenic overexpression of Cu/ZnSOD (shown to alleviate DSS-induced colitis), and GPx1/GPx2 (or GSH biosynthesis inhibitors like buthionine sulfoximine), hold promise as therapeutic options for reducing inflammation and treating IBD [107,119,120]. The gene discussed is NFKB1; the disease is inflammatory bowel disease.